Nasdaq: FRMI

Business

Coastal Financial's Stock Slide Sparks Debate: Is the Pullback a Buying Opportunity or a Warning Sign?

Shares of Coastal Financial (CCB) have retreated sharply from recent highs, reigniting the debate over the fintech-focused bank's premium valuation. While long-term performance remains strong, current momentum is fading, leaving investors to weigh high growth expectations against traditional valuation metrics.

Feb 2, 2026

Business

Netflix's Ad Engine Fires Up: Why the Recent Stock Dip Could Be a Buying Opportunity

Despite a post-earnings sell-off, Netflix's burgeoning advertising business is laying the groundwork for sustained profit growth, presenting a potential value entry for long-term investors.

Feb 2, 2026

Business

Kura Sushi USA Gets Price Target Boost from Piper Sandler Amid Loyalty Program Revamp

Piper Sandler raises its price target on Kura Sushi USA (KRUS) following an investor meeting, citing potential from recent changes to its digital loyalty platform. The company also appointed a new marketing-focused director as it eyes U.S. expansion.

Feb 2, 2026

Business

Benchmark Boosts Chefs' Warehouse Target to $84, Citing 'Visible Momentum' and Expansion Drive

Analyst firm Benchmark increased its price target for specialty food distributor The Chefs' Warehouse (CHEF) to $84, maintaining a Buy rating. The move follows strong operational performance, including domestic acquisitions and double-digit international growth in the Middle East.

Feb 2, 2026

Business

Morgan Stanley Trims Wingstop Target but Stays Bullish on Long-Term Growth Trajectory

Despite a modest price target reduction, Morgan Stanley reaffirms its Overweight rating on Wingstop, citing the chicken wing chain's robust unit expansion and system-wide sales momentum as key drivers for its 2026 outlook.

Feb 2, 2026

Business

Cal-Maine Foods Weathers Price Normalization, Bets on Specialty Eggs with Strategic Acquisition

Stephens lowers price target on Cal-Maine Foods (CALM) citing near-term oversupply pressures, but the egg producer's long-term strategy remains focused on expanding its cage-free capacity through acquisition.

Feb 2, 2026

Business

Freedom Capital Bullish on Mama's Creations, Sees National Growth and Innovation Driving Stock to $16

Freedom Capital initiates coverage on Mama's Creations (MAMA) with a Buy rating and a $16 price target, citing the company's expanding national footprint, product innovation, and strong recent earnings as key growth catalysts in the fresh meal sector.

Feb 2, 2026

Business

IDEXX Laboratories Posts Strong Q4 2025, Driven by Diagnostic Innovation and Global Expansion

IDEXX Laboratories reports robust fourth-quarter and full-year 2025 results, with double-digit revenue growth fueled by record instrument placements and strategic innovations like InVue DX and CancerDx. The company provides a confident outlook for 2026, targeting continued organic growth despite sector headwinds.

Feb 2, 2026

Business

STKS Price Target Cut After Q4 Revenue Shortfall, But Analysts See Long-Term Upside

Lake Street Capital maintains a Buy rating on The ONE Group Hospitality (STKS) despite lowering its price target, citing a solid finish in a tough market and a clear growth runway through 2026.

Feb 2, 2026

Business

JPMorgan Boosts Celsius Target on PepsiCo Deal Momentum, Sees Alani Nu as Growth Engine

JPMorgan raises its price target for Celsius Holdings (CELH) to $77, citing upside potential from its deepening PepsiCo partnership and the expanding distribution of its Alani Nu brand ahead of Q4 earnings.

Feb 2, 2026

Business

Microsoft's $357 Billion Sell-Off: A Buying Opportunity or a Sign of Deeper Trouble?

Despite posting blockbuster profits, Microsoft shares plunged 10% after its latest earnings, erasing hundreds of billions in market value. We examine whether Wall Street's reaction to cloud growth and AI spending fears is an overreaction or a prudent pause.

Feb 2, 2026

Business

Piper Sandler Trims Price Target for Black Diamond Therapeutics Amid Model Review, Despite Recent Clinical Wins

Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.

Feb 2, 2026

Business

Altimmune Secures Analyst Backing as Pemvidutide Advances Toward Phase 3 MASH Trial

Barclays initiates coverage with an Overweight rating and $20 price target on Altimmune, citing strong fundamentals and pipeline potential. The biotech firm prepares to channel recent offering proceeds toward its pivotal Phase 3 development for metabolic liver disease treatment pemvidutide.

Feb 2, 2026

Business

ImmunityBio's Anktiva Shows Blockbuster Potential as Piper Sandler Eyes Label Expansion After QUILT Trial Data

Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.

Feb 2, 2026

Business

Garrett Motion Gains Analyst Favor as Zero-Emission Tech Fuels Growth Outlook

Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.

Feb 2, 2026

Business

Lexeo Therapeutics Faces Market Skepticism Despite Positive PKP2 Gene Therapy Data

H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.

Feb 2, 2026

Business

Goodyear Poised for Growth as Replacement Tire Market Gains Momentum

Analysts maintain a bullish outlook on Goodyear Tire & Rubber, citing strong potential in the replacement tire market and favorable inventory trends, with a median price target suggesting a 7% upside.

Feb 2, 2026

Business

Mobileye Eyes 2026 as Pivotal Year Amid Analyst Backing and Strategic Shifts

Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.

Feb 2, 2026

Business

Barclays Bullish on 4D Molecular Therapeutics, Sees M&A and Pricing Trends as Key Catalysts

Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.

Feb 2, 2026

Business

Korro Bio's KRRO-121 Emerges as Independent Value Driver, Sparking Analyst Upgrades

H.C. Wainwright and Chardan Capital upgrade Korro Bio (KRRO) to Buy, citing the independent potential of its RNA-editing asset KRRO-121 and strong preclinical data as key catalysts.

Feb 2, 2026